Last 12 months
Inside the activity.
0 purchase rows · 13 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 12 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 27, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 11 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 0 Read SEC document |
| April 27, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 10 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 25,000 Read SEC document |
| April 27, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
GiftCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 9 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Indirect · By DJP 2020 Trust Disclosed balance after: 32,802 Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionStock Appreciation Right · Derivative | 5,520 | $0.00 Strike: $145.24 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · derivative · entry 25 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,560 Underlying: Common Stock · 5,520 shares Expires 2030-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on January 29, 2021. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionStock Appreciation Right · Derivative | 9,330 | $0.00 Strike: $139.06 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · derivative · entry 24 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,330 Underlying: Common Stock · 9,330 shares Expires 2029-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on January 30, 2020. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionStock Appreciation Right · Derivative | 24,015 | $0.00 Strike: $101.16 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · derivative · entry 23 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,005 Underlying: Common Stock · 24,015 shares Expires 2028-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The stock appreciation rights vest in four equal annual installments beginning on January 31, 2019. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionStock Appreciation Right · Derivative | 25,680 | $0.00 Strike: $81.96 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · derivative · entry 22 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,680 shares Expires 2027-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on February 1, 2018. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionStock Appreciation Right · Derivative | 23,910 | $0.00 Strike: $69.58 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · derivative · entry 21 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 23,910 shares Expires 2026-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on January 29, 2017. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionStock Appreciation Right · Derivative | 24,000 | $0.00 Strike: $68.96 | $0.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · derivative · entry 20 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on February 4, 2016. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
SaleCommon Stock | 37,305 | $200.03 | $7,462,130.34 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 8 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,903.9415 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.00 to $200.50, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes 2,068.9415 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Tax withholdingCommon Stock | 74,065 | $202.50 | $14,998,162.50 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 7 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,208.9415 F1 · balance_after: Includes 2,068.9415 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionCommon Stock | 5,520 | $145.24 | $801,724.80 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 6 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,273.9415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,068.9415 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionCommon Stock | 9,330 | $139.06 | $1,297,429.80 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 5 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,753.9415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,068.9415 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionCommon Stock | 24,015 | $101.16 | $2,429,357.40 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 4 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,423.9415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,068.9415 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionCommon Stock | 25,680 | $81.96 | $2,104,732.80 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 3 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,408.9415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,068.9415 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionCommon Stock | 23,910 | $69.58 | $1,663,657.80 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 2 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,728.9415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,068.9415 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 23, 2021 Filed Apr 27, 2021 20:19 UTC |
Perlin Jonathan BPres-Clinical Operations & CMO
|
Exercise / conversionCommon Stock | 24,000 | $68.96 | $1,655,040.00 |
DisclosureSEC source: 0001209191-21-028737 · doc4.xml · nonDerivative · entry 1 Perlin Jonathan B · CIK 0001373493 · Pres-Clinical Operations & CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,818.9415 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 2,068.9415 shares acquired under the HCA Holdings, Inc. Employee Stock Purchase Plan. Read SEC document |
| April 20, 2021 Filed Apr 20, 2021 20:15 UTC |
Foster Jon MGroup President
|
SaleCommon Stock | 5,504 | $194.90 | $1,072,729.60 |
DisclosureSEC source: 0001209191-21-027689 · doc4.xml · nonDerivative · entry 3 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,838 F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 20:15 UTC |
Foster Jon MGroup President
|
Exercise / conversionStock Appreciation Right · Derivative | 12,000 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-21-027689 · doc4.xml · derivative · entry 7 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 12,000 shares Expires 2024-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on February 5, 2015. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 20:15 UTC |
Foster Jon MGroup President
|
Tax withholdingCommon Stock | 6,496 | $196.93 | $1,279,257.28 |
DisclosureSEC source: 0001209191-21-027689 · doc4.xml · nonDerivative · entry 2 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,342 F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| April 16, 2021 Filed Apr 20, 2021 20:15 UTC |
Foster Jon MGroup President
|
Exercise / conversionCommon Stock | 12,000 | $47.97 | $575,640.00 |
DisclosureSEC source: 0001209191-21-027689 · doc4.xml · nonDerivative · entry 1 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 10, 2021 Filed Mar 10, 2021 19:13 UTC |
Foster Jon MGroup President
|
SaleCommon Stock | 5,432 | $186.18 | $1,011,329.76 |
DisclosureSEC source: 0001209191-21-019636 · doc4.xml · nonDerivative · entry 3 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,838 F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 19:15 UTC |
Riley Wayne JosephDirector
|
SaleCommon Stock | 1,650 | $190.00 | $313,500.00 |
DisclosureSEC source: 0001209191-21-019639 · doc4.xml · nonDerivative · entry 1 Riley Wayne Joseph · CIK 0001432895 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,819 F1 · kind: The sale of shares reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 19:13 UTC |
Foster Jon MGroup President
|
Exercise / conversionStock Appreciation Right · Derivative | 12,000 | $0.00 Strike: $47.97 | $0.00 |
DisclosureSEC source: 0001209191-21-019636 · doc4.xml · derivative · entry 7 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Underlying: Common Stock · 12,000 shares Expires 2024-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · derivative.exercise_date: The stock appreciation rights vested in four equal annual installments beginning on February 5, 2015. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 19:13 UTC |
Foster Jon MGroup President
|
Tax withholdingCommon Stock | 6,568 | $189.21 | $1,242,731.28 |
DisclosureSEC source: 0001209191-21-019636 · doc4.xml · nonDerivative · entry 2 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,270 F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 19:13 UTC |
Foster Jon MGroup President
|
Exercise / conversionCommon Stock | 12,000 | $47.97 | $575,640.00 |
DisclosureSEC source: 0001209191-21-019636 · doc4.xml · nonDerivative · entry 1 Foster Jon M · CIK 0001513235 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,838 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The exercise of stock appreciation rights and sale of shares reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 19:33 UTC |
WATERMAN ROBERT ASVP & General Counsel
|
SaleCommon Stock | 4,100 | $175.32 | $718,809.13 |
DisclosureSEC source: 0001209191-21-014497 · doc4.xml · nonDerivative · entry 4 WATERMAN ROBERT A · CIK 0001216856 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 278,849 F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.00 to $175.69, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 19:33 UTC |
WATERMAN ROBERT ASVP & General Counsel
|
SaleCommon Stock | 43,990 | $176.36 | $7,758,287.55 |
DisclosureSEC source: 0001209191-21-014497 · doc4.xml · nonDerivative · entry 3 WATERMAN ROBERT A · CIK 0001216856 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,949 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.80 to $176.71, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 19:33 UTC |
WATERMAN ROBERT ASVP & General Counsel
|
SaleCommon Stock | 12,266 | $177.00 | $2,171,056.24 |
DisclosureSEC source: 0001209191-21-014497 · doc4.xml · nonDerivative · entry 2 WATERMAN ROBERT A · CIK 0001216856 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,939 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $176.72 to $177.71, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 19:33 UTC |
WATERMAN ROBERT ASVP & General Counsel
|
SaleCommon Stock | 13,497 | $178.20 | $2,405,181.60 |
DisclosureSEC source: 0001209191-21-014497 · doc4.xml · nonDerivative · entry 1 WATERMAN ROBERT A · CIK 0001216856 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,205 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.75 to $178.695, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2021 Filed May 4, 2021 19:42 UTC |
Wyatt Christopher F.SVP & Controller
|
GiftCommon Stock | 433 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-030118 · doc4.xml · nonDerivative · entry 1 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,747 Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 19:31 UTC |
Englebright Jane D.SVP and Chief Nursing Officer
|
SaleCommon Stock | 2,090 | $174.06 | $363,791.88 |
DisclosureSEC source: 0001209191-21-014496 · doc4.xml · nonDerivative · entry 3 Englebright Jane D. · CIK 0001632834 · SVP and Chief Nursing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,509 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $173.54 to $174.52, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 19:31 UTC |
Englebright Jane D.SVP and Chief Nursing Officer
|
SaleCommon Stock | 3,061 | $175.03 | $535,773.87 |
DisclosureSEC source: 0001209191-21-014496 · doc4.xml · nonDerivative · entry 2 Englebright Jane D. · CIK 0001632834 · SVP and Chief Nursing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,599 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $174.54 to $175.52, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 19:31 UTC |
Englebright Jane D.SVP and Chief Nursing Officer
|
SaleCommon Stock | 600 | $175.75 | $105,448.02 |
DisclosureSEC source: 0001209191-21-014496 · doc4.xml · nonDerivative · entry 1 Englebright Jane D. · CIK 0001632834 · SVP and Chief Nursing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,660 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.58 to $176.00, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 20:48 UTC |
Wyatt Christopher F.SVP & Controller
|
SaleCommon Stock | 3,200 | $177.06 | $566,579.52 |
DisclosureSEC source: 0001209191-21-013013 · doc4.xml · nonDerivative · entry 3 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,180 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.02 to $177.15, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 19, 2021 Filed Feb 22, 2021 20:37 UTC |
Berres JenniferSVP & Chief Human Res. Officer
|
SaleCommon Stock | 6,692 | $176.05 | $1,178,126.60 |
DisclosureSEC source: 0001209191-21-012990 · doc4.xml · nonDerivative · entry 3 Berres Jennifer · CIK 0001793262 · SVP & Chief Human Res. Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,380 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $175.70 to $176.65, inclusive. The reporting person undertakes to provide to HCA Healthcare, Inc., any security holder of HCA Healthcare, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:48 UTC |
Wyatt Christopher F.SVP & Controller
|
Tax withholdingCommon Stock | 2,360 | $174.61 | $412,079.60 |
DisclosureSEC source: 0001209191-21-013013 · doc4.xml · nonDerivative · entry 2 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,380 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:48 UTC |
Wyatt Christopher F.SVP & Controller
|
GrantCommon Stock | 8,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013013 · doc4.xml · nonDerivative · entry 1 Wyatt Christopher F. · CIK 0001673365 · SVP & Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,740 F1 · kind: On January 31, 2018, the reporting person was granted 4,980 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2018-2020. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2018-2020 earnings per share, the number of performance share units that vested equaled 162.88% of the units granted. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:47 UTC |
Whalen Kathleen MSVP & Chief Ethics Officer
|
Tax withholdingCommon Stock | 2,575 | $174.61 | $449,620.75 |
DisclosureSEC source: 0001209191-21-013011 · doc4.xml · nonDerivative · entry 3 Whalen Kathleen M · CIK 0001763910 · SVP & Chief Ethics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,763 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:47 UTC |
Whalen Kathleen MSVP & Chief Ethics Officer
|
GrantCommon Stock | 6,091 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013011 · doc4.xml · nonDerivative · entry 2 Whalen Kathleen M · CIK 0001763910 · SVP & Chief Ethics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,338 F2 · kind: On October 31, 2018, the reporting person was granted 3,740 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2018-2020. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2018-2020 earnings per share, the number of performance share units that vested equaled 162.88% of the units granted. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:47 UTC |
Whalen Kathleen MSVP & Chief Ethics Officer
|
GrantCommon Stock | 2,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013011 · doc4.xml · nonDerivative · entry 1 Whalen Kathleen M · CIK 0001763910 · SVP & Chief Ethics Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,247 F1 · kind: On January 31, 2018, the reporting person was granted 1,370 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2018-2020. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2018-2020 earnings per share, the number of performance share units that vested equaled 162.88% of the units granted. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:47 UTC |
WATERMAN ROBERT ASVP & General Counsel
|
Tax withholdingCommon Stock | 5,583 | $174.61 | $974,847.63 |
DisclosureSEC source: 0001209191-21-013010 · doc4.xml · nonDerivative · entry 2 WATERMAN ROBERT A · CIK 0001216856 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,702 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:47 UTC |
WATERMAN ROBERT ASVP & General Counsel
|
GrantCommon Stock | 14,186 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013010 · doc4.xml · nonDerivative · entry 1 WATERMAN ROBERT A · CIK 0001216856 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 358,285 F1 · kind: On January 31, 2018, the reporting person was granted 8,710 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2018-2020. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2018-2020 earnings per share, the number of performance share units that vested equaled 162.88% of the units granted. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:46 UTC |
Sowell Joseph A IIISVP; Chief Development Officer
|
Tax withholdingCommon Stock | 3,160 | $174.61 | $551,767.60 |
DisclosureSEC source: 0001209191-21-013008 · doc4.xml · nonDerivative · entry 2 Sowell Joseph A III · CIK 0001478415 · SVP; Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,357 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:46 UTC |
Sowell Joseph A IIISVP; Chief Development Officer
|
GrantCommon Stock | 10,147 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013008 · doc4.xml · nonDerivative · entry 1 Sowell Joseph A III · CIK 0001478415 · SVP; Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,517 F1 · kind: On January 31, 2018, the reporting person was granted 6,230 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2018-2020. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2018-2020 earnings per share, the number of performance share units that vested equaled 162.88% of the units granted. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:47 UTC |
Torres Kathryn A.SVP-Payer Contracting & Align.
|
Tax withholdingCommon Stock | 3,192 | $174.61 | $557,355.12 |
DisclosureSEC source: 0001209191-21-013009 · doc4.xml · nonDerivative · entry 2 Torres Kathryn A. · CIK 0001680636 · SVP-Payer Contracting & Align. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,316 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:47 UTC |
Torres Kathryn A.SVP-Payer Contracting & Align.
|
GrantCommon Stock | 8,111 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013009 · doc4.xml · nonDerivative · entry 1 Torres Kathryn A. · CIK 0001680636 · SVP-Payer Contracting & Align. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,508 F1 · kind: On January 31, 2018, the reporting person was granted 4,980 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2018-2020. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2018-2020 earnings per share, the number of performance share units that vested equaled 162.88% of the units granted. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:46 UTC |
RUTHERFORD BILL BCFO and EVP
|
Tax withholdingCommon Stock | 11,522 | $174.61 | $2,011,856.42 |
DisclosureSEC source: 0001209191-21-013007 · doc4.xml · nonDerivative · entry 2 RUTHERFORD BILL B · CIK 0001216850 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,306 Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:46 UTC |
RUTHERFORD BILL BCFO and EVP
|
GrantCommon Stock | 31,419 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-013007 · doc4.xml · nonDerivative · entry 1 RUTHERFORD BILL B · CIK 0001216850 · CFO and EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,828 F1 · kind: On January 31, 2018, the reporting person was granted 19,290 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2018-2020. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 80% of target) to two times the units granted (for actual performance of 120% or more of target). Based upon the Company's achievement with respect to cumulative 2018-2020 earnings per share, the number of performance share units that vested equaled 162.88% of the units granted. Read SEC document |
| February 18, 2021 Filed Feb 22, 2021 20:45 UTC |
Reiner Deborah MSVP - Mktg. & Communications
|
Tax withholdingCommon Stock | 1,567 | $174.61 | $273,613.87 |
DisclosureSEC source: 0001209191-21-013006 · doc4.xml · nonDerivative · entry 2 Reiner Deborah M · CIK 0001720832 · SVP - Mktg. & Communications 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,008 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.